LICENSE, MARKETING AND DEVELOPMENT AGREEMENT BY AND BETWEEN ANTHROGENESIS CORPORATION, D/B/A CCT AND ALLIQUA, INC. NOVEMBER 14, 2013License, Marketing and Development Agreement • November 27th, 2013 • Celgene Corp /De/ • Pharmaceutical preparations • New York
This LICENSE, MARKETING AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of November 14, 2013 (the “Effective Date”) by and between ANTHROGENESIS CORPORATION, D/B/A CELGENE CELLULAR THERAPEUTICS (“CCT”), a New Jersey corporation having a principal place of business at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (“CCT”), and ALLIQUA, INC., a Florida corporation having a principal place of business at 2150 Cabot Boulevard West, Langhorne, Pennsylvania (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
STOCK PURCHASE AGREEMENT BY AND BETWEEN CELGENE CORPORATION AND ALLIQUA, INC. NOVEMBER 14, 2013Stock Purchase Agreement • November 27th, 2013 • Celgene Corp /De/ • Pharmaceutical preparations • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of November 14, 2013, by and between Alliqua, Inc., a Florida corporation (the “Company”), and Celgene Corporation, a Delaware corporation (“Investor”).
SUPPLY AGREEMENT BY AND BETWEEN ANTHROGENESIS CORPORATION AND ALLIQUA, INC. NOVEMBER 14, 2013Supply Agreement • November 27th, 2013 • Celgene Corp /De/ • Pharmaceutical preparations • New York
THIS SUPPLY AGREEMENT (this “Agreement”) dated as of November 14, 2013 (the “Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua, Inc., a Florida corporation (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
